argenx SE

ARGXNASDAQ

FcRn antibody technology

Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-10-02. Published by ClinicalInvestor. Educational analysis only. Read the editorial policy and disclosures.

text updated 2026-10-02 · archived: kept for reference, not maintained · where each field comes from

Key figures from SEC filings

We have not parsed a 10-Q or 10-K for ARGX yet, so this page shows no cash, burn or runway figure rather than an estimate. Revenue stage: Commercial.

Upcoming catalysts

Company-specific dates below are registry milestones or filings we have linked. For FDA decision dates site-wide, see the PDUFA calendar.

No upcoming catalyst for argenx SE has been confirmed against a primary source. Rather than estimate one, this section is left empty — check the company's investor relations page and ClinicalTrials.gov directly.

Pipeline

DrugIndicationPhaseExpected data
VyvgartGeneralized Myasthenia GravisApprovedNot disclosed▼
Vyvgart HytruloCIDPApprovedNot disclosed▼
EmpasiprubartKidney transplant rejectionPhase 2Not disclosed▼

What does argenx SE do?

argenx developed Vyvgart which lowers harmful antibody levels by blocking FcRn receptor. Approved for myasthenia gravis and tested for many autoimmune diseases. One of the most promising platform stories in biotech with over $3B cash. Key risk is competition from other FcRn drugs.

What to watch

1

CIDP Phase 3 data mid-2026

2

Vyvgart revenue growth

3

UCB competitive data

4

ITP results 2026

5

International launch

Investment thesis

Moderate Risk

Bull case

Dominant FcRn franchise with Vyvgart blockbuster. Same drug tested across CIDP ITP pemphigus myositis. Strong $3.2B cash. Peak sales exceed $8B. Platform validated across diseases.

Bear case

Intense FcRn competition. Label expansion failures possible. Pricing pressure. High valuation. Manufacturing complexity.

Risk factors

⚠

FcRn competition

⚠

Label expansion failures

⚠

Pricing pushback

⚠

Manufacturing challenges

⚠

Market access

Trade ARGX commission-free on Webullvia Webull · Affiliate

Comparable companies

Sponsored

Get premium ARGX analysis on Seeking Alpha

Affiliate link — we may earn a commission at no cost to you

Disclaimer: This page is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Clinical trial analysis reflects publicly available data and AI-generated interpretations. Biotech investing carries significant risk including potential total loss of investment. Always verify critical claims through primary sources and consult a qualified financial advisor. Some links on this page are affiliate links. Review our editorial policy and disclosures.

Sponsor's late-stage trial record

Argenx has 58 Phase 2 or 3 studies on ClinicalTrials.gov: 20 completed, 8 stopped early, 30 ongoing.

20

Completed

8

Stopped early

30

Ongoing

Stopped early

  • ReALiSePhase 2 · started 2024 · terminated

    ARGX-119 in amyotrophic lateral sclerosis · n=60

    Reason given: The study was terminated following review of interim data indicating that continuation was unlikely to demonstrate a clinically meaningful treatment effect. The decision was made to minimize unnecessary participant burden.

  • UplighTEDPhase 3 · started 2024 · terminated

    Efgartigimod PH20 SC in thyroid eye disease · n=105

    Reason given: The pre-defined interim analysis concluded that continuing the trials is unlikely to demonstrate the intended efficacy. This decision is not related to safety concerns, and the safety profile of efgartigimod remains unchanged

  • UplighTEDPhase 3 · started 2024 · terminated

    Efgartigimod PH20 SC in thyroid eye disease · n=102

    Reason given: The pre-defined interim analysis concluded that continuing the trials is unlikely to demonstrate the intended efficacy. This decision is not related to safety concerns, and the safety profile of efgartigimod remains unchanged.

  • POTSPhase 2 · started 2023 · terminated

    Efgartigimod in post-covid postural orthostatic tachycardia syndrome postural orthostatic tachycardia syndrome · n=33

    Reason given: Due to the phase 2 results of the main study (ARGX-113-2104) showing that efgartigimod-treated PC-POTS patients had no clinically meaningful improvement, the decision has been made to terminate this open-label extension study (ARGX-113-2105) study.

  • BALLAD+Phase 3 · started 2023 · terminated

    efgartigimod PH20 SC in bullous pemphigoid · n=64

    Reason given: Sponsor decision

  • NCT05810961Phase 2 · started 2023 · terminated

    efgartigimod IV in membranous nephropathy · n=8

    Reason given: Sponsor decision

  • ADDRESS+Phase 3 · started 2021 · terminated

    efgartigimod PH20 SC in pemphigus vulgaris · n=183

    Reason given: Based on the lack of observed efficacy in the primary study ARGX-113-1904, the sponsor decided to discontinue the open-label extension study.

  • ADVANCE2Phase 3 · started 2020 · withdrawn

    efgartigimod in primary immune thrombocytopenia (itp) · n=0

    Reason given: The ARGX-113-1908 study will be replaced by a similar design with a subcutaneous formulation (ARGX-113-2004)

Counts cover interventional Phase 2 and Phase 3 studies registered under this sponsor name, retrieved 2026-09-28 from ClinicalTrials.gov API v2. Trials stop for many reasons — futility, safety, enrollment, funding, or a decision to back a different programme — and the registry often does not say which. This is the sponsor's record, not a prediction about any specific readout.